Tissue repair and regeneration: in search of a more effective treatment
Our R&D at the service of people for better living
to improve skin healing
Medical equipement :
to fight against physiological aging of the skin Dermo-cosmetics :

Regentis Pharma

Innovation serving Better Living

Based on more than 30 years of experience in matrikines (synthetic peptides derived from extracellular matrix and able to stimulate tissue regeneration), Regentis Pharma is the EU leader in discovery of synthetic peptides for tissue regeneration.

Regentis Pharma is a spin-off of Reims Champagne Ardennes University and the SFR-Cap Santé incorporated in 2008.  Regentis Pharma is an innovative biotechnology company specializing in the development and marketing of medical treatments and devices related to tissue regeneration. The expertise of Regentis Pharma is the discovery of synthetic bifunctional peptides in tissue regeneration for cosmetic, medical device & pharmaceutical applications.

Regentis Pharma aims to collaborate with partners in order to develop together new medical devices. Regentis-Pharma’s business model is to license innovative bifunctional peptide to private partners, in the fields of dermo-cosmetics, medical devices, pathology treatments (periodontal diseases, severe burns or diabetic foot ulcers).

The expertise of Regentis-Pharma is the discovery of synthetic peptides in tissue regeneration for cosmetic, medical device & pharmaceutical applications.

Cutaneous wound healing

Régentis-Pharma develops medical devices able to decrease inflammatory reaction and to improve the quality of wound healing.

Periodontal diseases

Our laboratory investigates a better efficacy for treatments of periodontal diseases: gingivitis and periodontitis.

Dermo-cosmetics

Régentis-Pharma has developed an innovative anti-aging cosmetic product that has been the subject of clinical trials in humans.

Clinical trial of an anti-aging dermo cosmetic product

The clinical trial ended in 2020 and positive results on an anti-aging effect of our cream were obtained. A cream […]

Development of a medical device for the treatment of gum inflammation

Regentis-Pharma received an Eurostars (European) funding for the development of a new medical device for the treatment of gum pathologies […]

Participation in the congress « Journées cicatrisations 2020 » in Paris

Regentis-Pharma participated in the congress “Journées cicatrisations 2020”, organised by the « Société Française et Francophone des Plaies et Cicatrisations […]